Amivantamab Approved for EGFR-mutated NSCLC

The FDA approved amivantamab (Rybrevant; Janssen Biotech) with chemotherapy for non–small cell lung cancer (NSCLC) with EGFR exon 19 deletions or exon 21 L858R substitution mutations. Approval is limited to patients whose disease has progressed after with an EGFR tyrosine kinase inhibitor. In the MARIPOSA-2 trial, progression-free survival was 6.3 months for patients receiving amivantamab and chemotherapy and 4.2 months for patients receiving chemotherapy alone, although there was no significant difference in overall survival.